This paper investigates whether glycoprotein 6 (GP6) gene polymorphisms are a risk factor for recurrent pregnancy loss (RPL) in Korean women. Genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism and real-time polymerase chain reaction amplification. We identified five polymorphisms in the GP6 gene: rs1654410 T>C, rs1671153 T>G, rs1654419 G>A, rs12610286 A>G, and rs1654431 G>A. GP6 rs1654410 CC was associated with decreased RPL risk (adjusted odds ratio = 0.292, 95% confidence interval = 0.105–0.815, p = 0.019), and recessive genotypes were also significantly associated with decreased RPL risk (adjusted odds ratio = 0.348, 95% confidence interval = 0.128−0.944, p = 0.038). GP6 rs1654419 GA was associated with decreased RPL risk (adjusted odds ratio = 0.607, 95% confidence interval = 0.375-0.982, p = 0.042), and dominant genotypes were significantly associated with decreased RPL risk (adjusted odds ratio = 0.563, 95% confidence interval = 0.358−0.885, p = 0.013). Altogether, the genotype frequencies of GP6 rs1654410 T>C and GP6 rs1654419 G>A were significantly different between RPL patients and control participants. Therefore, although GP6 polymorphisms may be useful as biomarkers of RPL, additional studies with heterogeneous cohorts are required to better understand the influence of GP6 and assess its performance as a biomarker.

中文翻译：

---

血小板特异性胶原受体糖蛋白 6 基因变体、选定的生物标志物与韩国女性复发性妊娠丢失之间的关联

本文研究了糖蛋白 6 (GP6) 基因多态性是否是韩国女性反复流产 (RPL) 的危险因素。通过聚合酶链反应限制性片段长度多态性和实时聚合酶链反应扩增确定基因型。我们在 GP6 基因中发现了五个多态性：rs1654410 T>C、rs1671153 T>G、rs1654419 G>A、rs12610286 A>G 和 rs1654431 G>A。GP6 rs1654410 CC 与 RPL 风险降低相关（调整优势比 = 0.292，95% 置信区间 = 0.105–0.815，p = 0.019），隐性基因型也与 RPL 风险降低显着相关（调整优势比 = 0.348，95% 置信区间 = 0.105–0.815，p = 0.019）置信区间 = 0.128−0.944，p = 0.038）。GP6 rs1654419 GA 与 RPL 风险降低相关（调整后的优势比 = 0.607，95% 置信区间 = 0.375-0。982，p = 0.042），显性基因型与 RPL 风险降低显着相关（调整后的优势比 = 0.563，95% 置信区间 = 0.358−0.885，p = 0.013）。总之，GP6 rs1654410 T>C 和 GP6 rs1654419 G>A 的基因型频率在 RPL 患者和对照参与者之间存在显着差异。因此，尽管 GP6 多态性可能用作 RPL 的生物标志物，但需要对异质队列进行额外研究，以更好地了解 GP6 的影响并评估其作为生物标志物的性能。A 在 RPL 患者和对照参与者之间有显着差异。因此，尽管 GP6 多态性可能用作 RPL 的生物标志物，但需要对异质队列进行额外研究，以更好地了解 GP6 的影响并评估其作为生物标志物的性能。A 在 RPL 患者和对照参与者之间有显着差异。因此，尽管 GP6 多态性可能用作 RPL 的生物标志物，但需要对异质队列进行额外研究，以更好地了解 GP6 的影响并评估其作为生物标志物的性能。